Scarica l'app Stockscreener
166.08
0.04%
-0.06
Pre-mercato:
168.00
1.92
+1.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca stock holds steady amid licensing deal for novel Lp(a) inhibitor - ad-hoc-news.de
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Yahoo Finance
AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook - ad-hoc-news.de
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN) - Seeking Alpha
AstraZeneca breast cancer drug fails late-stage trial goal By Investing.com - Investing.com Nigeria
AstraZeneca's breast cancer pill fails in late-stage trial - Reuters
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment - Seeking Alpha
AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline - ad-hoc-news.de
AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal - marketscreener.com
AstraZeneca breast cancer drug fails late-stage trial goal - investing.com
AstraZeneca Says Breast Cancer Pill Fails in Key Study - Bloomberg.com
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - marketscreener.com
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - AstraZeneca
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN) - Yahoo Finance
AstraZeneca Halts Early Lung Cancer Imaging Trial: What Investors Should Watch Next - TipRanks
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
AstraZeneca stock gains as analysts see upside ahead of next earnings - ad-hoc-news.de
AstraZeneca stock heads into the open after a modest London gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 0.93% gain - ad-hoc-news.de
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? - Yahoo Finance
AstraZeneca’s New Cholesterol Combo Trial Could Reshape Its Heart-Health Portfolio - TipRanks
Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained - marketscreener.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche - Proactive financial news
AstraZeneca stock edges higher as Deutsche Bank sticks to Sell after COPD data - ad-hoc-news.de
AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success - ad-hoc-news.de
AstraZeneca PLC : Gets a Sell rating from Deutsche Bank - marketscreener.com
Can AstraZeneca (LSE:AZN) Stock Extend Its Rally On A Fresh Wave Of Oncology Approvals? - Kalkine Media
AstraZeneca stock heads into the open after a modest September 9, 2026 gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 2.0 percent drop - ad-hoc-news.de
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough - GuruFocus
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive Investors
AstraZeneca stock gains analyst support as RBC sets 14,500p target - ad-hoc-news.de
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - ad-hoc-news.de
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
AstraZeneca falls Tuesday, underperforms market - MarketWatch
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca sees positive results from lung cancer drug trial - Sharecast.com
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
AstraZeneca (LSE:AZN) slumps today as combination chatter grips London pharma? - Kalkine Media
REGAstraZeneca PLCImfinzi+Imdelltra improved OS in small cell lung - TradingView
AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials - marketscreener.com
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
0.39%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):